Business
GenSight Biologics Announces Closing of Fundraising Worth Nearly EUR 2.9 Million
PARIS, January 07, 2026--Regulatory News: NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA
About this update from Gensight Biologics Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":204,"url":"https://media.zenfs.com/en/business-wire.com/a1794ac740c6a9050484fb050ddd2dfe"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Yw1Q9dM8rvrqxAh5KaBPqA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQwODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/a1794ac740c6a9050484fb050ddd2dfe","width":480,"height":204}},"lazy":false},{"type":"text","content":"PARIS, January 07, 2026--(BUSINESS WIRE)--Regulatory News:","length":58,"tagName":"p"},{"type":"text","content":"NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA","length":120,"tagName":"p","attribs":{}},{"type":"text","content":"GenSight Biologics (the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the closing of its EUR 2,894,715.96 fundraising (the "Fundraising").","length":361,"tagName":"p"},{"type":"text","content":"The Fundraising resulted in the issuance of:","length":44,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"30,433,950 ordinary shares (actions ordinaires) of the Company (the "Offered Shares"), which were admitted to trading on Euronext Paris on December 31, 2025 (ISIN FR0013183985/SIGHT);","length":193,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"6,571,428 pre-funded warrants (the "Offered Pre-Funded Warrants") giving the right to subscribe to 6,571,428 additional ordinary shares; and","length":150,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"37,005,378 warrants (the "Offered Investor Warrants") giving the right to subscribe to 37,005,378 additional ordinary shares.","length":135,"tagName":"p","attribs":{}}]}],"tagName":"ol","bulletedList":false,"length":478},{"type":"text","content":"The Offered Investor Warrants and the Offered Pre-Funded Warrants will not be admitted to trading on any venue.","length":111,"tagName":"p"},{"type":"text","content":"Risk factors","length":12,"tagName":"p"},{"type":"text","content":"The Company draws the ...